We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

48 hedge funds and large institutions have $205M invested in Akero Therapeutics in 2019 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

39.46% more ownership

Funds ownership: 0% → 39.46% (+39%)

Holders
48
Holders Change
+48
Holders Change %
–
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
48
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VP
venBio Partners
California
+$75M
2
RG
Redmile Group
California
+$22.2M
3
CAM
Cormorant Asset Management
Massachusetts
+$14.6M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$14.4M
5
BI
BVF Inc
California
+$12.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VP
1
venBio Partners
California
$75.7M +$75M +3,954,858 New
RG
2
Redmile Group
California
$22.4M +$22.2M +1,168,802 New
CAM
3
Cormorant Asset Management
Massachusetts
$14.7M +$14.6M +767,842 New
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$14.6M +$14.4M +761,153 New
BI
5
BVF Inc
California
$12.4M +$12.3M +648,348 New
HA
6
HHLR Advisors
Cayman Islands
$8.14M +$8.06M +425,000 New
BC
7
Boxer Capital
California
$7.6M +$7.52M +396,695 New
Wellington Management Group
8
Wellington Management Group
Massachusetts
$6.36M +$6.3M +332,160 New
HIM
9
Hillhouse Investment Management
Cayman Islands
$5.7M +$5.64M +297,521 New
RSCM
10
Rock Springs Capital Management
Maryland
$4.31M +$4.26M +225,000 New
Alkeon Capital Management
11
Alkeon Capital Management
New York
$4.23M +$4.19M +221,000 New
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$3.86M +$3.82M +201,500 New
Millennium Management
13
Millennium Management
New York
$3.21M +$3.18M +167,746 New
FCM
14
Farallon Capital Management
California
$2.87M +$2.84M +150,000 New
BlackRock
15
BlackRock
New York
$2.8M +$2.77M +146,162 New
OAM
16
Oxford Asset Management
United Kingdom
$2.17M +$2.15M +113,308 New
MIM
17
Monashee Investment Management
Massachusetts
$2.11M +$2.08M +110,000 New
Adage Capital Partners
18
Adage Capital Partners
Massachusetts
$1.85M +$1.83M +96,721 New
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$1.24M +$1.23M +64,688 New
Goldman Sachs
20
Goldman Sachs
New York
$1.11M +$1.1M +58,164 New
MWNA
21
Marshall Wace North America
New York
$1.04M +$1.03M +54,304 New
CPIG
22
Chicago Partners Investment Group
Illinois
$676K +$572K +30,200 New
DIM
23
DC Investments Management
Virginia
$627K +$621K +32,752 New
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$575K +$569K +30,000 New
Vanguard Group
25
Vanguard Group
Pennsylvania
$574K +$569K +30,000 New
1
2

AKRO Hedge Fund Activity: Q2 2019 in Review

48 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2019, worth a combined $205M.

Buyers outnumbered sellers: 48 funds opened new AKRO positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was venBio Partners, opening a new position worth an estimated $75M.

  • 48 institutional investors held Akero Therapeutics (AKRO) as of Q2 2019, up from 0 in Q1 2019.
  • Funds reported $205M of Akero Therapeutics stock for Q2 2019.
  • 48 funds opened new Akero Therapeutics positions in Q2 2019 and 0 closed out, a net change of +48 holders.
  • The largest Akero Therapeutics buyer in Q2 2019 was venBio Partners, an estimated $75M added.

Based on aggregated 13F filings for Q2 2019.